GPX8 and idiopathic pulmonary fibrosis: Future studies should focus on overcoming the limitations of the current research and explore the following promising directions: First, large-scale multi-center studies should validate the clinical utility of identified biomarkers (such as GPX8, COMP, and ASPN) in different IPF populations to determine their potential as diagnostic tools.